Orthopoxvirus inhibitors that are active in animal models: An update from 2008 to 2012

Future Virology

Volumn 8, Issue 9, 2013, Pages 891-901

  Smee, Donald F ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

antiviral; camelpox; cowpox; drug combinations; ectromelia; monkeypox; rabbitpox; smallpox; vaccinia

Indexed keywords

4' THIOIDOXURIDINE; ADENOVIRUS VECTOR; ALPHA INTERFERON; ANTIVIRUS AGENT; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CIDOFOVIR AZACITIDINE; CSA 13 CERAGENIN; CYCLIC CIDOFOVIR; HYPERIMMUNE GLOBULIN; IMATINIB; IMIQUIMOD; MDEF 201; MITOXANTRONE; NUCLEOSIDE DERIVATIVE; PHOSPHONOACETIC ACID; PROTEIN TYROSINE KINASE INHIBITOR; SOCS 1 MIMETIC; TECOVIRIMAT; THIOSEMICARBAZONE; UNCLASSIFIED DRUG; VACCINIA ANTIBODY;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; EXPERIMENTAL DOG; EXPERIMENTAL MODEL; EXPERIMENTAL MONKEY; EXPERIMENTAL MOUSE; EXPERIMENTAL RABBIT; HUMAN; MOLLUSCUM CONTAGIOSUM; NONHUMAN; ORTHOPOXVIRUS; POST EXPOSURE PROPHYLAXIS; POXVIRUS INFECTION; PRIORITY JOURNAL; PUBLICATION; REVIEW; SCIURIDAE; SMALLPOX; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VIRUS REPLICATION;

EID: 84883223927     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.76     Document Type: Review

References (83)

1. Cleri DJ, Porwancher RB, Ricketti AJ, Ramos-Bonner LS, Vernaleo Jr. Smallpox as a bioterrorist weapon: Myth or menace? Infect. Dis. Cin. North Am. 20(2), 329-357 (2006
2. Anderson PD, Bokor G. Bioterrorism: Pathogens as weapons. J. Pharm. Practice 25(5), 521-529 (2012
3. Russell PK. Project BioShield: What it is, why it is needed, and its accomplishments so far. Clin. Infect. Dis. 45(Suppl. 1), S68-S72 (2007
4. Russell PK, Gronvall GK. U.S. medical countermeasure development since 2001: A long way yet to go. Biosecur. Bioterror. 10(1), 66-76 (2012
5. Bray M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res. 58(2), 101-114 (2003
6. Bray M, Wright ME. Progressive vaccinia. Clin. Infect. Dis. 36(6), 766-774 (2003
7. Reed JL, Scott DE, Bray M. Eczema vaccinatum. Clin. Infect. Dis. 54(6), 832-840 (2012
8. Smee DF, Sidwell RW. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 57(1-2), 41-52 (2003
9. Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir. Chem. Chemother. 19(3), 115-124 (2008
10. Duraffour S, Matthys P, van den Oord JJ et al. Study of camelpox virus pathogenesis in athymic nude mice. PLoS ONE 6(6), e21561 (2011
11. Anderson MG, Frenkel LD, Homann S, Guffey J. A case of severe monkeypox virus disease in an American child: Emerging infections and changing professional values. Ped. Infect. Dis. J. 22(12), 1093-1096 (2003
12. Smith AL, St Claire M, Yellayi S et al. Intrabronchial inoculation of cynomolgus macaques with cowpox virus. J. Gen. Virol. 93(Pt 1), 159-164 (2012
13. Goff AJ, Chapman J, Foster C et al. A novel respiratory model of infection with monkeypox virus in cynomolgus macaques. J. Virol. 85(10), 4898-4909 (2011
14. Barnewall RE, Fisher DA, Robertson AB, Vales PA, Knostman KA, Bigger JE. Inhalational monkeypox virus infection in cynomolgus macaques. Front. Cell Infect. Microbiol. 2, 117 (2012
15. Goff A, Mucker E, Raymond J et al. Infection of cynomolgus macaques with a recombinant monkeypox virus encoding green fluorescent protein. Arch. Virol. 156(10), 1877-1881 (2011
16. Parker S, Buller RM. A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012. Future Virol. 8(2), 129-157 (2013
17. Jordan R, Hruby D. Smallpox antiviral drug development: Satisfying the animal efficacy rule. Expert Rev. Anti Infect. Ther. 4(2), 277-289 (2006
18. Duraffour S, Andrei G, Topalis D et al. Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus. J. Virol. 86(13), 7310-7325 (2012
19. Yang G, Pevear DC, Davies MH et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79(20), 13139-13149 (2005
20. Jordan R, Leeds JM, Tyavanagimatt S, Hruby DE. Development of ST-246® for treatment of poxvirus infections. Viruses 2(11), 2409-2435 (2010
21. Vora S, Damon I, Fulginiti V et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin. Infect. Dis. 46(10), 1555-1561 (2008
22. Wertheimer ER, Olive DS, Brundage JF, Clark LL. Contact transmission of vaccinia virus from smallpox vaccinees in the United States, 2003-2011. Vaccine 30(6), 985-988 (2012
23. Lederman ER, Davidson W, Groff HL et al. Progressive vaccinia: Case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J. Infect. Dis. 206(9), 1372-1385 (2012
24. Erickson C, Driscoll M, Gaspari A. Efficacy of intravenous cidofovir in the treatment of giant molluscum contagiosum in a patient with human immunodeficiency virus. Arch. Dermatol. 147(6), 652-654 (2011
25. Cohen JI, Davila W, Ali MA et al. Detection of molluscum contagiosum virus (MCV) DNA in the plasma of an immunocompromised patient and possible reduction of MCV DNA with CMX-001. J. Infect. Dis. 205(5), 794-797 (2012
26. Fisher RW, Reed JL, Snoy PJ et al. Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin. Clin. Vaccine Immunol. 18(1), 67-74 (2011
27. Neyts J, De Clercq E. Efficacy of (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl) cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 41(3), 242-246 (1993
28. Ciesla SL, Trahan J, Wan WB et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 59(3), 163-171 (2003
29. Lanier R, Trost L, Tippin T et al. Development of CMX001 for the treatment of poxvirus infections. Viruses 2(12), 2740-2762 (2010
30. Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob. Agents Chemother. 56(5), 2726-2734 (2012
31. Jordan R, Goff A, Frimm A et al. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: Determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 53(5), 1817-1822 (2009
32. Kuroda K, Fukuda T, Okumura K et al. Ceragenin CSA-13 induces cell cycle arrest and antiproliferative effects in wild-type and p53 null mutant HCT116 colon cancer cells. Anticancer Drugs 24(8), 826-834 (2013
33. Miller RL, Meng TC, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect. 21(2), 69-87 (2008
34. Overby LR, Duff RG, Mao JC. Antiviral potential of phosphonoacetic acid. Ann. NY Acad. Sci. 284, 310-320 (1977
35. Reeves PM, Bommarius B, Lebeis S et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 11(7), 731-739 (2005
36. Deng L, Dai P, Ciro A, Smee DF, Djaballah H, Shuman S. Identification of novel antipoxviral agents: Mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J. Virol. 81(24), 13392-13402 (2007
37. Kern ER, Prichard MN, Quenelle DC et al. Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections. Antimicrob. Agents Chemother. 53(2), 572-579 (2009
38. Neyts J, Verbeken E, De Clercq E. Effect of 5-iodo-2'-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 46(9), 2842-2847 (2002
39. Smee DF, Sidwell RW. Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides. Nucleosides Nucleotides Nucleic Acids 23(1-2), 375-383 (2004
40. Rus F, Morlock K, Silverman N, Pham N, Kotwal GJ, Marshall WL. Characterization of poxvirus-encoded proteins that regulate innate immune signaling pathways. Methods Mol. Biol. 890, 273-288 (2012
41. Smee DF, Bailey KW, Wong MH, Wandersee MK, Sidwell RW. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J. Infect. Dis. 190(6), 1132-1139 (2004
42. Quenelle DC, Prichard MN, Keith KA et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 51(11), 4118-4124 (2007
43. Reynolds MG, Damon IK. Outbreaks of human monkeypox after cessation of smallpox vaccination. Trends Microbiol. 20(2), 80-87 (2012
44. Parker S, Chen NG, Foster S et al. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - An animal model of smallpox. Antiviral Res. 94(1), 44-53 (2012
45. Smee DF, Gowen BB, Wandersee MK et al. Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment. Int. J. Antimicrob. Agents 31(4), 352-359 (2008
46. Parker S, Siddiqui AM, Oberle C et al. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies. Virology 385(1), 11-21 (2009
47. Luker KE, Luker GD. Applications of bioluminescence imaging to antiviral research and therapy: Multiple luciferase enzymes and quantitation. Antiviral Res. 78(3), 179-187 (2008
48. Zaitseva M, Kapnick SM, Scott J et al. Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice. J. Virol. 83(20), 10437-10447 (2009
49. Americo JL, Moss B, Earl PL. Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models. J. Virol. 84(16), 8172-8180 (2010
50. Earl PL, Americo JL, Moss B. Lethal monkeypox virus infection of CAST/EiJ mice is associated with a deficient gamma interferon response. J. Virol. 86(17), 9105-9112 (2012
51. Stabenow J, Buller RM, Schriewer J, West C, Sagartz JE, Parker S. A mouse model of lethal infection for evaluating prophylactics and therapeutics against monkeypox virus. J. Virol. 84(8), 3909-3920 (2010
52. Schultz DA, Sagartz JE, Huso DL, Buller RM. Experimental infection of an African dormouse (Graphiurus kelleni) with monkeypox virus. Virology 383(1), 86-92 (2009
53. Hutson CL, Olson VA, Carroll DS et al. A prairie dog animal model of systemic orthopoxvirus disease using west African and Congo basin strains of monkeypox virus. J. Gen. Virol. 90(Pt 2), 323-333 (2009
54. Kramski M, Matz-Rensing K, Stahl-Hennig C et al. A novel highly reproducible and lethal nonhuman primate model for orthopox virus infection. PLoS ONE 5(4), e10412 (2010
55. Israely T, Paran N, Lustig S et al. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease. Virol. J. 9, 119 (2012
56. Verreault D, Sivasubramani SK, Talton JD et al. Evaluation of inhaled cidofovir as postexposure prophylactic in an aerosol rabbitpox model. Antiviral Res. 93(1), 204-208 (2012
57. Parker S, Schriewer J, Oberle C et al. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001. Antivir. Ther. 13(7), 863-873 (2008
58. Parker S, Touchette E, Oberle C et al. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res. 77(1), 39-49 (2008
59. Rice AD, Adams MM, Lampert B et al. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses 3(2), 63-82 (2011
60. Rice AD, Adams MM, Wallace G et al. Efficacy of CMX001 as a post exposure antiviral in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses 3(1), 47-62 (2011
61. Huggins J, Goff A, Hensley L et al. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 53(6), 2620-2625 (2009
62. Smith SK, Self J, Weiss S et al. Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox. J. Virol. 85(17), 9176-9187 (2011
63. Nalca A, Hatkin JM, Garza NL et al. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res. 79(2), 121-127 (2008
64. Berhanu A, King DS, Mosier S et al. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob. Agents Chemother. 53(12), 4999-5009 (2009
65. Grosenbach DW, Berhanu A, King DS et al. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc. Natl Acad. Sci. USA 107(2), 838-843 (2010
66. Santos-Fernandes E, Beltrame CO, Byrd CM et al. Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®. Antiviral Res. 97(3), 301-311 (2013
67. Howell MD, Streib JE, Kim BE et al. Ceragenins: A class of antiviral compounds to treat orthopox infections. J. Invest. Dermatol. 129(11), 2668-2675 (2009
68. Smee DF, Bailey KW, Wong MH, Tarbet EB. Topical treatment of cutaneous vaccinia virus infections in immunosuppressed hairless mice with selected antiviral substances. Antivir. Chem. Chemother. 21(5), 201-208 (2011
69. Gammon DB, Snoeck R, Fiten P et al. Mechanism of antiviral drug resistance of vaccinia virus: Identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs. J. Virol. 82(24), 12520-12534 (2008
70. Reeves PM, Smith SK, Olson VA et al. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. J. Virol. 85(1), 21-31 (2011
71. Tarbet EB, Larson D, Anderson BJ, Bailey KW, Wong MH, Smee DF. Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice. Antiviral Res. 90(3), 126-133 (2011
72. Smee DF, Wong MH, Russell A, Ennis J, Turner JD. Therapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201). PLoS ONE 6(10), e26330 (2011
73. Altmann SE, Smith AL, Dyall J et al. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res. 93(2), 305-308 (2012
74. Ahmed CM, Dabelic R, Waiboci LW, Jager LD, Heron LL, Johnson HM. SOCS-1 mimetics protect mice against lethal poxvirus infection: Identification of a novel endogenous antiviral system. J. Virol. 83(3), 1402-1415 (2009
75. Chen N, Bellone CJ, Schriewer J et al. Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis, and antiviral therapy. Virology 409(2), 328-337 (2011
76. Bolken TC, Hruby DE. Discovery and development of antiviral drugs for biodefense: Experience of a small biotechnology company. Antiviral Res. 77(1), 1-5 (2008
77. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art. Antiviral Res. 82(2), A84-A98 (2009
78. De Clercq E. Historical perspectives in the development of antiviral agents against poxviruses. Viruses 2(6), 1322-1339 (2010
79. Hostetler KY. Synthesis and early development of hexadecyloxypropyl cidofovir: An oral antipoxvirus nucleoside phosphonate. Viruses 2(10), 2213-2225 (2010
80. Quenelle DC, Kern ER. Treatment of vaccinia and cowpox virus infections in mice with CMX001 and ST-246. Viruses 2(12), 2681-2695 (2010
81. Roy CJ, Voss TG. Use of the aerosol rabbitpox virus model for evaluation of anti-poxvirus agents. Viruses 2(9), 2096-2107 (2010
82. Nalca A, Nichols DK. Rabbitpox: A model of airborne transmission of smallpox. J. Gen. Virol. 92(Pt 1), 31-35 (2011
83. Prichard MN, Kern ER. Orthopoxvirus targets for the development of new antiviral agents. Antiviral Res. 94(2), 111-125 (2012